GrippeAllemagneV4, Main, Exploration, bibRecord, 000013

Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.

Identifieur interne : 000013 ( Main/Exploration ); précédent : 000012; suivant : 000014

Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.

Auteurs : Manas K. Akmatov [Allemagne] ; Peggy Riese [Allemagne] ; Stephanie Trittel [Allemagne] ; Marcus May [Allemagne] ; Jana Prokein [Allemagne] ; Thomas Illig [Allemagne] ; Christoph Schindler [Allemagne] ; Carlos A. Guzmán [Allemagne] ; Frank Pessler [Allemagne]

Source :

BMC infectious diseases [ 1471-2334 ] ; 2019.

RBID : pubmed:31337344

Descripteurs français

KwdFr :
- Adjuvants immunologiques (pharmacologie), Allemagne (MeSH), Antigènes viraux (immunologie), Autorapport (MeSH), Diabète (immunologie), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Humains (MeSH), Immunité humorale (MeSH), Mâle (MeSH), Saisons (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (pharmacologie), Zona (immunologie), Études prospectives (MeSH).
MESH :
- effets indésirables : Vaccins antigrippaux.
- immunologie : Antigènes viraux, Diabète, Grippe humaine, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux, Zona.
- pharmacologie : Adjuvants immunologiques, Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- Allemagne, Autorapport, Femelle, Humains, Immunité humorale, Mâle, Saisons, Sujet âgé, Sujet âgé de 80 ans ou plus, Études prospectives.
Wicri :
- geographic : Allemagne.

English descriptors

KwdEn :
- Adjuvants, Immunologic (pharmacology), Aged (MeSH), Aged, 80 and over (MeSH), Antigens, Viral (immunology), Diabetes Mellitus (immunology), Female (MeSH), Germany (MeSH), Herpes Zoster (immunology), Humans (MeSH), Immunity, Humoral (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H3N2 Subtype (immunology), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza Vaccines (pharmacology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male (MeSH), Prospective Studies (MeSH), Seasons (MeSH), Self Report (MeSH).
MESH :
- chemical , adverse effects : Influenza Vaccines.
- chemical , immunology : Antigens, Viral, Influenza Vaccines.
- chemical , pharmacology : Adjuvants, Immunologic, Influenza Vaccines.
- geographic : Germany.
- immunology : Diabetes Mellitus, Herpes Zoster, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza, Human.
- prevention & control : Influenza, Human.
- Aged, Aged, 80 and over, Female, Humans, Immunity, Humoral, Male, Prospective Studies, Seasons, Self Report.

Abstract

BACKGROUND

The immune response to seasonal influenza vaccines decreases with advancing age. Therefore, an adjuvanted inactivated trivalent influenza vaccine (Fluad®) exists for elderly individuals. Fluad® is more immunogenic and efficacious than conventional influenza vaccines. However, the immune response varies and may still result in high frequencies of poor responders. Therefore, we aimed to a) examine the prevalence of a weak response to Fluad® and b) identify potential risk factors.

METHODS

A prospective population-based study among individuals 65-80 years old was conducted in 2015/2016 in Hannover, Germany (n = 200). Hemagglutination-inhibition titers 21 days after vaccination with Fluad® served as indicator of vaccine responsiveness.

RESULTS

The percentage of vaccinees with an inadequate vaccine response varied depending on the influenza strain: it was lowest for H3N2 (13.5%; 95% CI, 9.4-18.9%), intermediate for B strain (37.0%; 30.6-43.9%), and highest for H1N1 (49.0%; 42.2-55.9%). The risk of a weak response to the influenza A H1N1 strain was independently associated with self-reported diabetes (AOR, 4.64; 95% CI, 1.16-18.54), a history of herpes zoster (2.27; 1.01-5.10) and, to a much lesser extent, increasing age (change per year, 1.08; 0.99-1.16). In addition, herpes zoster was the only risk factor for a weak response to the H3N2 antigen (AOR, 3.12; 1.18-8.23). We found no significant association between sex, Body Mass Index, cancer, hypertension, heart attack and CMV seropositivity and a weak response to these two influenza A antigens. Despite its occurence in over one third of vaccinees, none of the variables examined proved to be risk factors for a weak response to the B antigen.

CONCLUSIONS

A considerable proportion of elderly individuals displayed a weak vaccine response to this adjuvanted seasonal influenza vaccine and further efforts are thus needed to improve immune responses to influenza vaccination among the elderly. Diabetes and herpes zoster were identified as potentially modifiable risk factors for a poor vaccine response against influenza A antigens, but the results also reveal the need for broader investigations to identify risk factors for inadequate responses to influenza B antigens.

TRIAL REGISTRATION

No. NCT02362919 (ClinicalTrials.gov, date of registration: 09.02.2015).

DOI: 10.1186/s12879-019-4214-x
PubMed: 31337344
PubMed Central: PMC6651912

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000012
to stream Main, to step Curation: 000012

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.</title>
<author><name sortKey="Akmatov, Manas K" sort="Akmatov, Manas K" uniqKey="Akmatov M" first="Manas K" last="Akmatov">Manas K. Akmatov</name>
<affiliation wicri:level="1"><nlm:affiliation>Helmholtz Centre for Infection Research, Braunschweig, Germany. makmatov@zi.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany. makmatov@zi.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Centre for Individualised Infection Medicine, Hannover, Germany. makmatov@zi.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Centre for Individualised Infection Medicine, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Riese, Peggy" sort="Riese, Peggy" uniqKey="Riese P" first="Peggy" last="Riese">Peggy Riese</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trittel, Stephanie" sort="Trittel, Stephanie" uniqKey="Trittel S" first="Stephanie" last="Trittel">Stephanie Trittel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="May, Marcus" sort="May, Marcus" uniqKey="May M" first="Marcus" last="May">Marcus May</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Research Center Hannover, Hannover Medical School, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Clinical Research Center Hannover, Hannover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Prokein, Jana" sort="Prokein, Jana" uniqKey="Prokein J" first="Jana" last="Prokein">Jana Prokein</name>
<affiliation wicri:level="3"><nlm:affiliation>Hannover Unified Biobank, Hanover Medical School, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Hannover Unified Biobank, Hanover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Illig, Thomas" sort="Illig, Thomas" uniqKey="Illig T" first="Thomas" last="Illig">Thomas Illig</name>
<affiliation wicri:level="3"><nlm:affiliation>Hannover Unified Biobank, Hanover Medical School, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Hannover Unified Biobank, Hanover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schindler, Christoph" sort="Schindler, Christoph" uniqKey="Schindler C" first="Christoph" last="Schindler">Christoph Schindler</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Research Center Hannover, Hannover Medical School, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Clinical Research Center Hannover, Hannover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzmán">Carlos A. Guzmán</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre for Individualised Infection Medicine, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Centre for Individualised Infection Medicine, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pessler, Frank" sort="Pessler, Frank" uniqKey="Pessler F" first="Frank" last="Pessler">Frank Pessler</name>
<affiliation wicri:level="1"><nlm:affiliation>Helmholtz Centre for Infection Research, Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Centre for Individualised Infection Medicine, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Centre for Individualised Infection Medicine, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31337344</idno>
<idno type="pmid">31337344</idno>
<idno type="doi">10.1186/s12879-019-4214-x</idno>
<idno type="pmc">PMC6651912</idno>
<idno type="wicri:Area/Main/Corpus">000012</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000012</idno>
<idno type="wicri:Area/Main/Curation">000012</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000012</idno>
<idno type="wicri:Area/Main/Exploration">000012</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.</title>
<author><name sortKey="Akmatov, Manas K" sort="Akmatov, Manas K" uniqKey="Akmatov M" first="Manas K" last="Akmatov">Manas K. Akmatov</name>
<affiliation wicri:level="1"><nlm:affiliation>Helmholtz Centre for Infection Research, Braunschweig, Germany. makmatov@zi.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany. makmatov@zi.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Centre for Individualised Infection Medicine, Hannover, Germany. makmatov@zi.de.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Centre for Individualised Infection Medicine, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Riese, Peggy" sort="Riese, Peggy" uniqKey="Riese P" first="Peggy" last="Riese">Peggy Riese</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Trittel, Stephanie" sort="Trittel, Stephanie" uniqKey="Trittel S" first="Stephanie" last="Trittel">Stephanie Trittel</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="May, Marcus" sort="May, Marcus" uniqKey="May M" first="Marcus" last="May">Marcus May</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Research Center Hannover, Hannover Medical School, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Clinical Research Center Hannover, Hannover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Prokein, Jana" sort="Prokein, Jana" uniqKey="Prokein J" first="Jana" last="Prokein">Jana Prokein</name>
<affiliation wicri:level="3"><nlm:affiliation>Hannover Unified Biobank, Hanover Medical School, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Hannover Unified Biobank, Hanover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Illig, Thomas" sort="Illig, Thomas" uniqKey="Illig T" first="Thomas" last="Illig">Thomas Illig</name>
<affiliation wicri:level="3"><nlm:affiliation>Hannover Unified Biobank, Hanover Medical School, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Hannover Unified Biobank, Hanover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schindler, Christoph" sort="Schindler, Christoph" uniqKey="Schindler C" first="Christoph" last="Schindler">Christoph Schindler</name>
<affiliation wicri:level="3"><nlm:affiliation>Clinical Research Center Hannover, Hannover Medical School, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Clinical Research Center Hannover, Hannover Medical School, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzmán">Carlos A. Guzmán</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre for Individualised Infection Medicine, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Centre for Individualised Infection Medicine, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pessler, Frank" sort="Pessler, Frank" uniqKey="Pessler F" first="Frank" last="Pessler">Frank Pessler</name>
<affiliation wicri:level="1"><nlm:affiliation>Helmholtz Centre for Infection Research, Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Helmholtz Centre for Infection Research, Braunschweig</wicri:regionArea>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
<wicri:noRegion>Braunschweig</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Centre for Individualised Infection Medicine, Hannover, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Centre for Individualised Infection Medicine, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">BMC infectious diseases</title>
<idno type="eISSN">1471-2334</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (pharmacology)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Antigens, Viral (immunology)</term>
<term>Diabetes Mellitus (immunology)</term>
<term>Female (MeSH)</term>
<term>Germany (MeSH)</term>
<term>Herpes Zoster (immunology)</term>
<term>Humans (MeSH)</term>
<term>Immunity, Humoral (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (pharmacology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male (MeSH)</term>
<term>Prospective Studies (MeSH)</term>
<term>Seasons (MeSH)</term>
<term>Self Report (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (pharmacologie)</term>
<term>Allemagne (MeSH)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Autorapport (MeSH)</term>
<term>Diabète (immunologie)</term>
<term>Femelle (MeSH)</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Humains (MeSH)</term>
<term>Immunité humorale (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Saisons (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (pharmacologie)</term>
<term>Zona (immunologie)</term>
<term>Études prospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term>
<term>Diabète</term>
<term>Grippe humaine</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Zona</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Diabetes Mellitus</term>
<term>Herpes Zoster</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Immunity, Humoral</term>
<term>Male</term>
<term>Prospective Studies</term>
<term>Seasons</term>
<term>Self Report</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term>
<term>Autorapport</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunité humorale</term>
<term>Mâle</term>
<term>Saisons</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études prospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>The immune response to seasonal influenza vaccines decreases with advancing age. Therefore, an adjuvanted inactivated trivalent influenza vaccine (Fluad®) exists for elderly individuals. Fluad® is more immunogenic and efficacious than conventional influenza vaccines. However, the immune response varies and may still result in high frequencies of poor responders. Therefore, we aimed to a) examine the prevalence of a weak response to Fluad® and b) identify potential risk factors.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>A prospective population-based study among individuals 65-80 years old was conducted in 2015/2016 in Hannover, Germany (n = 200). Hemagglutination-inhibition titers 21 days after vaccination with Fluad® served as indicator of vaccine responsiveness.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>The percentage of vaccinees with an inadequate vaccine response varied depending on the influenza strain: it was lowest for H3N2 (13.5%; 95% CI, 9.4-18.9%), intermediate for B strain (37.0%; 30.6-43.9%), and highest for H1N1 (49.0%; 42.2-55.9%). The risk of a weak response to the influenza A H1N1 strain was independently associated with self-reported diabetes (AOR, 4.64; 95% CI, 1.16-18.54), a history of herpes zoster (2.27; 1.01-5.10) and, to a much lesser extent, increasing age (change per year, 1.08; 0.99-1.16). In addition, herpes zoster was the only risk factor for a weak response to the H3N2 antigen (AOR, 3.12; 1.18-8.23). We found no significant association between sex, Body Mass Index, cancer, hypertension, heart attack and CMV seropositivity and a weak response to these two influenza A antigens. Despite its occurence in over one third of vaccinees, none of the variables examined proved to be risk factors for a weak response to the B antigen.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>A considerable proportion of elderly individuals displayed a weak vaccine response to this adjuvanted seasonal influenza vaccine and further efforts are thus needed to improve immune responses to influenza vaccination among the elderly. Diabetes and herpes zoster were identified as potentially modifiable risk factors for a poor vaccine response against influenza A antigens, but the results also reveal the need for broader investigations to identify risk factors for inadequate responses to influenza B antigens.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>TRIAL REGISTRATION</b>
</p>
<p>No. NCT02362919 (ClinicalTrials.gov, date of registration: 09.02.2015).</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31337344</PMID>
<DateCompleted><Year>2019</Year>
<Month>10</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>02</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>19</Volume>
<Issue>1</Issue>
<PubDate><Year>2019</Year>
<Month>Jul</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>BMC infectious diseases</Title>
<ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.</ArticleTitle>
<Pagination><MedlinePgn>656</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-019-4214-x</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The immune response to seasonal influenza vaccines decreases with advancing age. Therefore, an adjuvanted inactivated trivalent influenza vaccine (Fluad®) exists for elderly individuals. Fluad® is more immunogenic and efficacious than conventional influenza vaccines. However, the immune response varies and may still result in high frequencies of poor responders. Therefore, we aimed to a) examine the prevalence of a weak response to Fluad® and b) identify potential risk factors.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A prospective population-based study among individuals 65-80 years old was conducted in 2015/2016 in Hannover, Germany (n = 200). Hemagglutination-inhibition titers 21 days after vaccination with Fluad® served as indicator of vaccine responsiveness.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The percentage of vaccinees with an inadequate vaccine response varied depending on the influenza strain: it was lowest for H3N2 (13.5%; 95% CI, 9.4-18.9%), intermediate for B strain (37.0%; 30.6-43.9%), and highest for H1N1 (49.0%; 42.2-55.9%). The risk of a weak response to the influenza A H1N1 strain was independently associated with self-reported diabetes (AOR, 4.64; 95% CI, 1.16-18.54), a history of herpes zoster (2.27; 1.01-5.10) and, to a much lesser extent, increasing age (change per year, 1.08; 0.99-1.16). In addition, herpes zoster was the only risk factor for a weak response to the H3N2 antigen (AOR, 3.12; 1.18-8.23). We found no significant association between sex, Body Mass Index, cancer, hypertension, heart attack and CMV seropositivity and a weak response to these two influenza A antigens. Despite its occurence in over one third of vaccinees, none of the variables examined proved to be risk factors for a weak response to the B antigen.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A considerable proportion of elderly individuals displayed a weak vaccine response to this adjuvanted seasonal influenza vaccine and further efforts are thus needed to improve immune responses to influenza vaccination among the elderly. Diabetes and herpes zoster were identified as potentially modifiable risk factors for a poor vaccine response against influenza A antigens, but the results also reveal the need for broader investigations to identify risk factors for inadequate responses to influenza B antigens.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">No. NCT02362919 (ClinicalTrials.gov, date of registration: 09.02.2015).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akmatov</LastName>
<ForeName>Manas K</ForeName>
<Initials>MK</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-2310-3179</Identifier>
<AffiliationInfo><Affiliation>Helmholtz Centre for Infection Research, Braunschweig, Germany. makmatov@zi.de.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany. makmatov@zi.de.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine, Hannover, Germany. makmatov@zi.de.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Riese</LastName>
<ForeName>Peggy</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Trittel</LastName>
<ForeName>Stephanie</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>May</LastName>
<ForeName>Marcus</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Clinical Research Center Hannover, Hannover Medical School, Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Prokein</LastName>
<ForeName>Jana</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Hannover Unified Biobank, Hanover Medical School, Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Illig</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Hannover Unified Biobank, Hanover Medical School, Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schindler</LastName>
<ForeName>Christoph</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Clinical Research Center Hannover, Hannover Medical School, Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Guzmán</LastName>
<ForeName>Carlos A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine, Hannover, Germany.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pessler</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Research Group "Biomarkers for Infectious Diseases", TWINCORE, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625, Hannover, Germany.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Centre for Individualised Infection Medicine, Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT02362919</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>BMC Infect Dis</MedlineTA>
<NlmUniqueID>100968551</NlmUniqueID>
<ISSNLinking>1471-2334</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C478243">fluad vaccine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006562" MajorTopicYN="N">Herpes Zoster</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056724" MajorTopicYN="Y">Immunity, Humoral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes</Keyword>
<Keyword MajorTopicYN="N">Elderly</Keyword>
<Keyword MajorTopicYN="N">Fluad®</Keyword>
<Keyword MajorTopicYN="N">Herpes zoster</Keyword>
<Keyword MajorTopicYN="N">Influenza vaccination</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>05</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>06</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>7</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>7</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>10</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31337344</ArticleId>
<ArticleId IdType="doi">10.1186/s12879-019-4214-x</ArticleId>
<ArticleId IdType="pii">10.1186/s12879-019-4214-x</ArticleId>
<ArticleId IdType="pmc">PMC6651912</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Int J Epidemiol. 1999 Oct;28(5):964-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10597998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stat Med. 2000 Apr 30;19(8):1059-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10790680</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann N Y Acad Sci. 2000 Jun;908:244-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10911963</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2001 Aug;3(10):851-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11580980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2002 Jan 1;185(1):114-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11756990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2003 Dec;42(6):1206-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14656957</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Gerontol. 2004 Oct;39(10):1447-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15501014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Feb 20;24(8):1159-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16213065</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2007 Jan;211(2):144-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17200946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 2007 Apr;120(4):435-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17313487</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biogerontology. 2009 Feb;10(1):83-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18563620</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Med Virol. 2009 Jan;19(1):47-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19035529</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Sep 12;26 Suppl 4:D35-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19230157</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Jul 15;200(2):172-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19508159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Dec 9;27(52):7304-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19849996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Klin (Munich). 2010 May;105(5):334-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20503007</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Geriatr Gerontol Int. 2011 Jan;11(1):63-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20738411</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immun Ageing. 2010 Sep 07;7:13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20822513</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Jun 24;29(29-30):4869-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21497631</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2011 Jun 16;11:173</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21679419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Obes (Lond). 2012 Aug;36(8):1072-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22024641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jun 6;30(26):3937-3943</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22484350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2012 Aug;11(8):985-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23002979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2013 Jan 11;31(4):685-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23196209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Chemother. 2013 Jun;45(2):159-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24265964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2015 Feb;70(2):178-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25230396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Mar;89(6):3308-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25589639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Control Hosp Epidemiol. 2015 Mar;36(3):249-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25695164</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2015 Apr 1;7(281):281ra43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25834109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2015 Jun 26;33(29):3306-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26044491</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2015 Apr 15;2(2):ofv052</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26380344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ Open Diabetes Res Care. 2015 Oct 13;3(1):e000140</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26504526</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS Res Treat. 2015;2015:653840</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26576297</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dtsch Arztebl Int. 2016 Mar 18;113(11):177-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27118665</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Res. 2016;2016:8426874</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27493973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gerontol A Biol Sci Med Sci. 2017 Sep 1;72(9):1163-1170</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27789617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 Jan 23;35(4):513-520</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28024956</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Med Res Methodol. 2017 Feb 2;17(1):18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28148221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Vaccine Res. 2017 Jan;6(1):38-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28168172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes Res. 2017;2017:6494795</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28251163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2017 Jul 3;13(7):1630-1639</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28394705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 May 15;35(21):2775-2780</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28431815</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stat Med. 1998 Apr 30;17(8):857-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9595616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Basse-Saxe</li>
</region>
<settlement><li>Hanovre</li>
</settlement>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Akmatov, Manas K" sort="Akmatov, Manas K" uniqKey="Akmatov M" first="Manas K" last="Akmatov">Manas K. Akmatov</name>
</noRegion>
<name sortKey="Akmatov, Manas K" sort="Akmatov, Manas K" uniqKey="Akmatov M" first="Manas K" last="Akmatov">Manas K. Akmatov</name>
<name sortKey="Akmatov, Manas K" sort="Akmatov, Manas K" uniqKey="Akmatov M" first="Manas K" last="Akmatov">Manas K. Akmatov</name>
<name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzmán">Carlos A. Guzmán</name>
<name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzmán">Carlos A. Guzmán</name>
<name sortKey="Illig, Thomas" sort="Illig, Thomas" uniqKey="Illig T" first="Thomas" last="Illig">Thomas Illig</name>
<name sortKey="May, Marcus" sort="May, Marcus" uniqKey="May M" first="Marcus" last="May">Marcus May</name>
<name sortKey="Pessler, Frank" sort="Pessler, Frank" uniqKey="Pessler F" first="Frank" last="Pessler">Frank Pessler</name>
<name sortKey="Pessler, Frank" sort="Pessler, Frank" uniqKey="Pessler F" first="Frank" last="Pessler">Frank Pessler</name>
<name sortKey="Pessler, Frank" sort="Pessler, Frank" uniqKey="Pessler F" first="Frank" last="Pessler">Frank Pessler</name>
<name sortKey="Prokein, Jana" sort="Prokein, Jana" uniqKey="Prokein J" first="Jana" last="Prokein">Jana Prokein</name>
<name sortKey="Riese, Peggy" sort="Riese, Peggy" uniqKey="Riese P" first="Peggy" last="Riese">Peggy Riese</name>
<name sortKey="Schindler, Christoph" sort="Schindler, Christoph" uniqKey="Schindler C" first="Christoph" last="Schindler">Christoph Schindler</name>
<name sortKey="Trittel, Stephanie" sort="Trittel, Stephanie" uniqKey="Trittel S" first="Stephanie" last="Trittel">Stephanie Trittel</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000013 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000013 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeAllemagneV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31337344
   |texte=   Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31337344" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV4

This area was generated with Dilib version V0.6.35.
Data generation: Mon Aug 10 17:53:30 2020. Site generation: Sat Mar 27 17:40:37 2021

	Serveur d'exploration sur la grippe en Allemagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Allemagne

Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.

Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1 vaccine antigen among the elderly.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki